Abstract
Background Endogenous DNA derived from nuclei or mitochondria is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with various pathological conditions; however, its clinical significance in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) remains unclear. This study aimed to evaluate the clinical significance of cfDNA in AAV.
Methods We enrolled 35 patients with AAV, including 10 with eosinophilic granulomatosis with polyangiitis (EGPA), 13 with microscopic polyangiitis, and 12 with granulomatosis with polyangiitis. Serum cf-nuclear DNA (cf-nDNA) and cf-mitochondrial DNA (cf-mtDNA) levels were measured by quantitative polymerase chain reaction. Tissue samples from EGPA patients were examined by immunofluorescence and transmission electron microscopy. The structure, stability, and platelet adhesion of eosinophil extracellular traps (EETs) were also assessed in vitro.
Results Serum cf-nDNA and cf-mtDNA levels were significantly higher in AAV than in healthy controls, with the highest levels in EGPA; however, serum DNase activities were comparable among all groups. cf-nDNA and cf-mtDNA decreased after treatment and were associated with disease activity only in EGPA. Blood eosinophil count and plasma D-dimer levels were significantly correlated with cf-nDNA in EGPA and cf-mtDNA. EGPA tissue samples showed lytic eosinophils and EETs in small-vessel thrombi. EETs showed greater stability against DNase than neutrophil extracellular traps and provided a scaffold for platelet adhesion in vitro.
Conclusion cfDNA was increased in EGPA, associated with disease activity. The presence of DNase-resistant EETs might contribute to the occurrence of immunothrombosis in EGPA.
Competing Interest Statement
S.U. reports grants and personal fees from AstraZeneca, personal fees from GlaxoSmithKline, and grants from Novartis and from Maruho Co. Ltd.; Y.K. reports personal fees from AstraZeneca; M.F. reports grants from GlaxoSmithKline; and K.M. reports grants from Asahikasei Pharma Co. and Chugai Pharma Co. during the conduct of the study.
Funding Statement
This study was funded in part by a Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development (JP20ek0410055 to SU), the Mochida Memorial Foundation for Medical and Pharmaceutical Research, AstraZeneca Evidence Connect Externally Sponsored Research (SU), the Japanese Society of Laboratory Medicine Fund for Promotion of Scientific Research (SU), JSPS KAKENHI (20K08794 to SU; 19K17898 to YK). This work was also supported by a Grant-in-Aid for Researchers, Hyogo College of Medicine, 2019 (TH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional ethics committees of Hyogo College of Medicine (approval no. 0374) and Akita University Graduate School of Medicine (approval no. 994).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos